November 19, 2026
Health news, explained with evidence
LIVE
Brepocitinib Shows Potential for Treating Cutaneous Sarcoidosis JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial Brepocitinib Shows Potential for Treating Cutaneous Sarcoidosis JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial

Brepocitinib Shows Potential for Treating Cutaneous Sarcoidosis

❤️ Conditions & Care 2 min read 👁 0

A Phase II clinical trial indicates that the medication brepocitinib may significantly reduce disease activity in patients suffering from cutaneous sarcoidosis.

Brepocitinib Shows Potential for Treating Cutaneous Sarcoidosis❤️Conditions & Care

Photo: Medical Xpress

Key points

  • Brepocitinib demonstrated significant improvements in CSAMI-A scores compared to placebo.
  • The 45-mg dose showed consistent clinical benefits across various disease activity endpoints.
  • The study was a Phase II, multicenter, randomized trial involving 31 participants.

A recent study published in JAMA Dermatology reports that brepocitinib, an experimental treatment, demonstrates clinical efficacy in managing cutaneous sarcoidosis (CS). Researchers from the Perelman School of Medicine at the University of Pennsylvania conducted a Phase II, randomized, placebo-controlled trial involving 31 adult participants. Patients received either 15 mg or 45 mg of the drug, or a placebo, once daily over a 16-week period.

The findings suggest that both dosage levels of brepocitinib led to notable improvements in CS disease activity compared to the placebo group. Participants in the treatment arms showed significant reductions in their Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) scores. The 45-mg dose, in particular, showed consistent efficacy across several clinical endpoints, including skin-related quality-of-life metrics and the achievement of clearer skin.

What to know: While these results are promising, the study was a Phase II trial with a limited sample size of 31 patients. Further large-scale research is required to confirm the long-term safety and effectiveness of this treatment. Patients should consult with their healthcare providers regarding current management options for sarcoidosis and to stay informed about emerging clinical trials.

These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients.

Source Medical Xpress — medicalxpress.com/news/2026-11-brepocitinib-yields-cutaneous-sarcoidosi… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.